=> b reg FILE 'REGISTRY' ENTERED AT 15:35:11 ON 28 SEP 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 SEP 2007 HIGHEST RN 948530-59-4 DICTIONARY FILE UPDATES: 27 SEP 2007 HIGHEST RN 948530-59-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta 110 L6 STR

Hy~N~Hy~N~Hy 1 2 3 4 5

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E9 C E1 N AT 1
ECOUNT IS E4 C E2 N AT 3
ECOUNT IS E9 C E1 N AT 5

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 5

STEREO ATTRIBUTES: NONE

L8 36708 SEA FILE=REGISTRY ABB=ON PLU=ON >=2 NC5-C6/ES L10 42 SEA FILE=REGISTRY SUB=L8 SSS FUL L6

100.0% PROCESSED 36708 ITERATIONS SEARCH TIME: 00.00.01

42 ANSWERS

=> d bib abs hitrn fhitstr 113 1
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> b hcap FILE 'HCAPLUS' ENTERED AT 15:35:37 ON 28 SEP 2007 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Sep 2007 VOL 147 ISS 15 FILE LAST UPDATED: 27 Sep 2007 (2007.0927/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d bib abs hitrn fhitstr 113 1
     ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2007 ACS on STN
L13
     2001:416931 HCAPLUS
AN
DN
     135:33495
     Arylamine derivatives and their use as anti-telomerase agent
TI
     Mailliet, Patrick; Riou, Jean-Francois; Mergny, Jean-Louis; Laoui,
IN
     Abdelazize; Lavelle, Francois; Petitgenet, Odile
PA
     Aventis Pharma S.A., Fr.
     PCT Int. Appl., 66 pp.
     CODEN: PIXXD2
DT
     Patent
     French
LΑ
FAN.CNT 1
     PATENT NO.
                            KIND
                                    DATE
                                                  APPLICATION NO.
                                                                            DATE
                            ----
                                                  -----
PΙ
     WO2001040218
                             A1
                                    20010607
                                                  2000WO-FR03310
                                                                            20001127 <--
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
              HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
              LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
              ZA, ZW
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                                  1999FR-0015031
     FR---2801588
                             A1
                                    20010601
                                                                            19991129 <--
```

EP---1244650 20021002 2000EP-0985339 EP---1244650 20030625 В1 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

2000CA-2392507

2000BR-0015992 ·

20001127 <--

20001127 <--

20001127 <--

20020301

20010607

20020806

HU-200204429 A2 20030428 2002HU-0004429 20001127 <--JP2003515604 20030507 2001JP-0541902 20001127 <--Т 2002EE-0000263 EE-200200263 Α 20030616 20001127 <--2000AT-0985339 AT----243692 Т 20030715 20001127 <--PT---1244650 2000PT-0985339 T 20031128 20001127 <--ES---2202206 Т3 20040401 2000ES-0985339 20001127 <--

US---6645964 2000US-0722361 В1 20031111 20001128 <--MX2002PA05276 20021107 2002MX-PA05276 20020527 <--A IN2002DN00540 Α 20040228 2002IN-DN00540 20020527 <--2002NO-0002528 NO2002002528 20020528 20020528 <--Α ZA2002004266 Α 20030828 2002ZA-0004266 20020528 <--BG----106753 Α 20030228 2002BG-0106753 20020529 <--US2004053966 A1 20040318 2003US-0658394 20030910 <--

PRAI 1999FR-0015031 Α 19991129 <--2000FR-0010561 20000811 А <--2000US-176632P P 20000119 <--2000US-218059P Р 20000713 <--2000WO-FR03310 W 20001127

B1

A1

Α

A1

2000US-0722361 **A3** OS MARPAT 135:33495

FR---2801588

CA---2392507

BR2000015992

Nitrogen heterocycles, especially diaminotriazines, were prepared for use as telomerase inhibitors and anticancer agents. Thus, 2-amino-4,6-dichloro-1,3,5-triazine was treated with 1-methyl-4,6-quinaldinium chloride hydrochloride to give 2-amino-4,6-bis(1-methyl-4-amino-6-quinaldinio)amino-1,3,5-triazine dichloride hydrochloride which was converted to its free base. The free base had a telomerase-inhibiting IC50 of 0.25 μM and a cytotoxic IC50 of 0.59-1.9 µM.

20001128

TT 343876-24-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)

TT 343876-24-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of triazinediamine derivs. as telomerase inhibitors and antitumor agents)

RN 343876-24-4 HCAPLUS

CN 4,6-Quinolinediamine, N6,N6'-2,4-pyrimidinediylbis[2-methyl-, trihydrochloride (9CI) (CA INDEX NAME)

●3 HCl

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr l16 tot

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 1971:435658 HCAPLUS

DN 75:35658

TI Antimalarials. "Distal" hydrazine derivatives of 7-chloroquinoline

AU Singh, Tara; Hoops, John F.; Biel, John H.; Hoya, Wallace K.; Stein, Robert George; Cruz, Deanna R.

CS Res. Lab., Aldrich Chem. Co., Inc., Milwaukee, WI, USA

SO Journal of Medicinal Chemistry (1971), 14(6), 532-5

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English
GI For diagram(s) see

GI For diagram(s), see printed CA Issue.

AB 7-Chloroquinolines (I) containing a hydrazine feature in the side chain attached at position 4, were prepared from 4,7-dichloroquinoline and 7-chloro-4-(3-bromo-1-methylpropylamino) quinoline by reacting with the required hydrazine, and were tested for the antimalarial activity against Plasmodium berghei in mice. 1,4-Bis(7-chloro-4-quinolylamino)-piperazine was the best, in which the end NH2 was substituted by a 2nd mol. of 7-chloroquinoline. It showed curative activity at 40 mg/kg, i.p., without toxicity even up to the maximum dose of 640 mg/kg. The I with a distal hydrazine, excluding active 1-[2-(7-chloro-4-quinolinylamino) - 2 - methylethyl] - 1 - methylhydrazine, were inactive, but were highly toxic. The I having a hydrazinium bromide feature, although found curative, were also quite toxic.

IT 23512-27-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 23512-27-8 HCAPLUS

CN 1,4-Piperazinediamine, N,N'-bis(7-chloro-4-quinolinyl)- (9CI) (CA INDEX NAME)

```
ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
L16
```

AN 1970:3335 HCAPLUS

72:3335

Antimalarial substances. XVIII. Synthetic schistosomicides. 13. Antimalarial and antischistosomal effects of proximal hydrazine and hydroxylamine analogs of chloroquine and quinacrine

Elslager, Edward F.; Tendick, Frank H.; Werbel, Leslie M.; Worth, Donald AU

Med. and Sci. Affairs Div., Parke, Davis and Co., Ann Arbor, MI, USA CS

Journal of Medicinal Chemistry (1969), 12(5), 970-4 SO CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

For diagram(s), see printed CA Issue. GI

Representative 4-(2,2-dialkylhydrazino)quinolines, 6 - chloro - 9 - (2,2 dialkylhydrazino) - 2-methoxyacridines, 12-(2,2-dialkylhydrazino)benz[b]acridines, 2,-2'-(benz[c]acridin-7-ylhydrazono)diethanol, 7-chloro-4 - [2- (dialkylamino) ethoxyamino) quinolines, and 6-chloro-9-[2-(dimethylamino)ethoxyamino]-2-methoxyacridine were synthesized to enable an assessment of the antiparasitic effects conferred by substituting a hydrazine or hydroxylamine moiety for the proximal amine function of chloroquine, quinacrine, and 7-[3-(octylamino)propylamino]benz[c]acridine relatives. The compds. were isolated in 3-92% yield by the condensation of 4,7-dichloroquinoline, 4-chloro-6-methoxyquinoline, 4-chloro-6-methoxyquinaldine, 6,9-dichloro-2-methoxyacridine, 12-chlorobenz[b]acridine, or 7-chlorobenz[c]acridine with the appropriate 1,1-dialkylhydrazine or 2-(dialkylamino)ethoxyamine in phenol or EtOH. Among them, 6-methoxy-4-(morpholinoamino)-quinaldine exhibited modest activity against Schistosoma mansoni in mice and effected a 28-51% reduction of live worms at drug-diet doses of 224-303 mg./kg. daily for 14 days. Six compds. were active against a normal strain of Plasmodium berghei in mice at doses ranging from 2.7-219 mg./kg./day for 6 days. 7-Chloro-4-(4-methyl-1-piperazinylamino)quinoline, and 4,4'-(1,4-piper-a zinediyldiimino)bis[7-chloroquinoline] (I) were approx. 28 and 27 times as potent as quinine, resp., against P. berghei, but I was highly cross-resistant with chloroquine. Structure-activity relations are discussed.

IT 23512-27-8P

> RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

23512-27-8 HCAPLUS

1,4-Piperazinediamine, N,N'-bis(7-chloro-4-quinoliny1)- (9CI) (CA INDEX NAME)

=> d his

L4

(FILE 'HOME' ENTERED AT 15:24:31 ON 28 SEP 2007)

FILE 'HCAPLUS' ENTERED AT 15:24:40 ON 28 SEP 2007 L1 1 US20040053966 /PN

FILE 'REGISTRY' ENTERED AT 15:25:28 ON 28 SEP 2007

FILE 'HCAPLUS' ENTERED AT 15:25:35 ON 28 SEP 2007 L2 TRA L1 1- RN : 73 TERMS

FILE 'REGISTRY' ENTERED AT 15:25:35 ON 28 SEP 2007

73 SEA L2 L3

54 L3 AND NC5-C6/ES

L5 1 L4 AND (N2C4 OR NCNC3 OR NC2NC2)/ES L6

STR

0 L6 L7

36708 >=2 NC5-C6/ES L8

L9 2 L6 SAM SUB=L8

L10 42 L6 FULL SUB=L8

SAV TEM J394C22AF/A L10

1 L10 AND L3 L11

FILE 'HCAPLUS' ENTERED AT 15:30:46 ON 28 SEP 2007

L12 9 L10

4 L12 AND (PY<=2000 OR AY<=2000 OR PRY<=2000) L13

SEL HIT RN L13 2-4

FILE 'REGISTRY' ENTERED AT 15:31:48 ON 28 SEP 2007

L14 2 E1-2

L15 1 L14 AND C22H20CL2N6

FILE 'HCAPLUS' ENTERED AT 15:33:06 ON 28 SEP 2007 L16

2 L15 AND L13

FILE 'HCAOLD' ENTERED AT 15:34:45 ON 28 SEP 2007

0 L10

L17